Our Semaglutide Protocol is $830 and includes:

✅ 2 month supply of Semaglutide medication

✅ Enough supplies for weekly self-injection

✅ Initial consultation

✅ Note: There is a $100 consultation initial fee due at the time of consultation (this will be deducted when you pay for the entire package)

The semaglutide injection is a 4-month protocol with weekly subcutaneous dosing as scheduled:

Week 1-4: 0.25mg

Week 5-8: 0.5mg

Week 9-12: 0.75mg

Week 13-16: 1.0mg

Our services include personalized weight loss plans, regular check-ins with our healthcare professionals, and access to the latest research and advancements in weight loss medication.


Our weight loss plans are tailored to your individual needs and goals. We provide personalized guidance and support to help you achieve long-term success.

Expert Guidance

Our Tirzepatide Protocol is $945 and includes:

✅ 12 week supply of Tirzepatide medication

Supplies necessary for once per week self injection

✅ Initial consultation

Note: $100 consultation fee is due at time of consultation (and deducted from package price when you pay for the package).

Are you ready to kickstart your weight-loss journey and schedule your initial consultation with our nurse practitioner? Click on the link below.

How our Weight Loss Protocol works

Schedule an initial zoom consultation with our nurse practitioner. During your consultation, she will review your medical history based on the pre-filled medical questionnaire. You will get a detailed education about the medication, mechanism of action, diet, and self-injection technique.

Step 1

After your consultation with the nurse practitioner, you make the complete payment, and the medication/ supplies are shipped to your home directly from the pharmacy.

Step 2

You will check in with us periodically as you lose weight. We monitor your progress. Based on your request you can continue getting the medication after payment. Our goal is to tailor your weight loss protocol and dosing according to your goals.

Step 3


Write your text here...


Semaglutide is a pharmaceutical compound initially formulated for the management of type 2 diabetes. Nevertheless, in recent years, researchers have also examined its possible application in weight management.

Semaglutide is administered at a larger dosage for weight loss purposes compared to its dosage for diabetes therapy. Administered on a weekly basis, this injection functions by stimulating GLP-1 receptors in the brain, resulting in decreased hunger and heightened sensations of satiety. Semaglutide can serve as an effective means for individuals grappling with obesity or overweight by curbing food consumption and facilitating weight reduction.

Semaglutide has demonstrated efficacy in facilitating weight loss during clinical trials. As an illustration, a study published in the New England Journal of Medicine in 2021 revealed that individuals who were administered semaglutide for a duration of 68 weeks experienced an average reduction of 15.3% in their body weight, in contrast to a mere 2.4% in the placebo group.

Eli Lilly and Company is currently developing the drug tirzepatide to treat type 2 diabetes. Additionally, it has been investigated for its possible application in weight control.

Similar to semaglutide, tirzepatide works by activating GLP-1 receptors in the brain, which makes you feel fuller and less hungry. Nevertheless, tirzepatide additionally triggers the activation of GIP receptors, hence promoting the release of insulin from the pancreas in response to the consumption of food. Tirzepatide, by selectively activating both GIP and GLP-1 receptors, has demonstrated superior efficacy in reducing blood glucose levels and inducing weight reduction compared to the use of GLP-1 receptor agonists alone.

Tirzepatide has demonstrated encouraging outcomes in facilitating weight reduction during clinical trials. As an illustration, a phase II clinical experiment published in The Lancet in 2021 revealed that individuals who were administered tripeptide for a duration of 26 weeks experienced an average reduction of 11.3% in their body weight, in contrast to a mere 2.4% observed in the placebo group.


Contact Us

For more information or to schedule a consultation, please contact us using the information below.